| Document |
Document Title |
|
WO/2024/153246A1 |
Provided are a compound of formula (I) which acts as a Cbl-b inhibitor, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition comprising the compound of formu...
|
|
WO/2024/153237A1 |
The present disclosure relates to compounds represented by formula I, and pharmaceutically acceptable salts, isotope-labeled substances or isomers thereof, which are IGF-1R kinase inhibitors and can be used for treating diseases such as ...
|
|
WO/2024/152296A1 |
Provided in the present invention are a chemiluminescent reagent for detecting mercaptan, a synthesis method and the use, belonging to the technical field of small-molecular chemiluminescent probes. The present invention comprises a subs...
|
|
WO/2024/140935A1 |
Antibody drug conjugates comprise an antibody or antigen binding fragment thereof capable of specific binding to human B7H3 and a cytotoxic agent, such as an exetecan analogue. A pharmaceutical composition comprises the antibody drug con...
|
|
WO/2024/141444A1 |
The invention relates to a compound of formula (I) wherein L, A1, R1, R2 and R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2024/144186A1 |
The present invention relates to a novel organic light-emitting compound and an organic electroluminescent diode using same and, more specifically, to: a compound having excellent thermal stability, electrochemical stability, light-emitt...
|
|
WO/2024/133211A1 |
The present invention relates to novel compounds and organic electroluminescent devices such as OLEDs (organic light emitting diodes) that contain these compounds, for example as electron transport materials and/or matrix materials, opti...
|
|
WO/2024/130570A1 |
A light emitting diode is provided. The light emitting diode includes a hole injection layer; and at least one of a hole transport layer or an electron barrier layer. The hole injection layer includes a host material doped with a guest m...
|
|
WO/2024/130342A1 |
The present invention relates to compounds, pharmaceutical compositions of said compounds, and uses of said compounds, especially for inhibition of Transient Receptor Potential channel family, Vanilloid subfamily member 6 (TRPV6). The co...
|
|
WO/2024/129601A1 |
Disclosed herein are compounds for use as muscle myosin inhibitors, along with methods for making and using the same. Compounds of the present disclosure can exhibit a selectivity for cardiac vs. skeletal myosin and do not inhibit non-mu...
|
|
WO/2024/126322A1 |
The present invention relates to compounds of a formula (I) or (II), processes for preparing compounds of this type, electronic devices, in particular OLEDs, containing one or more of these compounds, and the use of these compounds in el...
|
|
WO/2024/129780A1 |
The present disclosure provides a compounds of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, spe...
|
|
WO/2024/121552A1 |
The present invention provides Kv3 modulator compounds of the formula (I): and related aspects.
|
|
WO/2024/122617A1 |
The present invention provides a compound having an antagonist and/or inverse agonist action on the serotonin 5-HT2A receptor as well as an antagonist and/or inverse agonist action on the serotonin 5-HT2C receptor, or a pharmaceutically ...
|
|
WO/2024/117844A1 |
The present specification pertains to a compound of chemical formula 1 and an organic light-emitting element containing same.
|
|
WO/2024/119114A1 |
Provided herein are synthetic methods and intermediates useful in the preparation of polyketides. The polyketides include 12-membered ring macrolides. These synthetic methods and intermediates provide scalable access to polyketides, whic...
|
|
WO/2024/112439A1 |
Composition and efficient manufacturing processes for making up to 100% bio-based and upcycled renewable oils in batch and flow reactors using raw-materials, sourced from non-food biomass and/or inedible oil seeds/natural oils, is descri...
|
|
WO/2024/104464A1 |
The present invention provides a compound represented by formula (I), and a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof. The compound has a good Nav1.8 inhibitory effect.
|
|
WO/2024/103185A1 |
Disclosed are novel fused mescaline derivative compounds, notably substituted N-propylamine fused heterocyclic mescaline derivatives, including substituted N- propylamine fused dioxolane mescaline derivatives, and pharmaceutical and recr...
|
|
WO/2024/104473A1 |
Disclosed is a pyrene-based compound, having a structure as represented by chemical formula (I). The compound has a large molar extinction coefficient and fluorescence emission efficiency, and a color conversion layer made of the compoun...
|
|
WO/2024/101298A1 |
Disclosed are a method for producing pladienolide D that includes a step that reacts a compound represented by formula (A1) with a compound represented by formula (B1) in the presence of a metal catalyst to obtain a compound represented ...
|
|
WO/2024/097897A1 |
The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/...
|
|
WO/2024/094156A1 |
Provided is a compound represented by formula (I), or a stereoisomer thereof, an optical isomer thereof, a solvate thereof, an isotope derivative thereof, or a pharmaceutically acceptable salt thereof. The compound can be used as a ligan...
|
|
WO/2024/092864A1 |
A magnolol/glycosyl furan double-bio-based epoxy resin monomer, a preparation method therefor and a use thereof. The magnolol/glycosyl furan double-bio-based epoxy resin monomer is as shown in formula MF. A polymer material has a high gl...
|
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
|
WO/2024/088928A1 |
The invention relates to novel processes for manufacturing 6-[[5-methyl-3-(6-methyl-3- pyridyl)isoxazol-4-yl]methoxy]-N-tetrahydropyran-4-yl-pyrida
zine-3-carboxamide (1), or a pharmaceutically acceptable salt thereof. The processes acco...
|
|
WO/2024/088296A1 |
The present disclosure relates to a piperidinopyrimidine derivative, a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a piperidinopyrimidine derivative as represented by gener...
|
|
WO/2024/085354A1 |
The present invention provides, in the present specification, a heterocyclic compound and an organic light-emitting device including same.
|
|
WO/2024/080361A1 |
The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The compound of the invention has excellent α1A adrenergic receptor agonist activity and is useful as a proph...
|
|
WO/2024/070902A1 |
Provided is a compound represented by formula (1). (In the formula, R1 represents a hydrogen atom or a methyl group; R2 represents an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, an aryl group whi...
|
|
WO/2024/073129A1 |
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
|
|
WO/2024/072108A1 |
The present invention relates to a novel crystalline form of enavogliflozin, and a preparation method therefor. The novel crystalline form of enavogliflozin, according to the present invention, has thermodynamic stability and a hygroscop...
|
|
WO/2024/066916A1 |
Disclosed are an aromatic amine compound comprising a quaterphenyl structure and an organic electroluminescent device comprising the same. The aromatic amine compound has a structure represented by formula (I). The compound has the follo...
|
|
WO/2024/072109A1 |
The present invention relates to a co-crystal of enavogliflozin. The enavogliflozin co-crystal of the present invention increased the solubility of enavogliflozin in artificial gastric fluid and artificial intestinal fluid. This improvem...
|
|
WO/2024/073502A1 |
The present disclosure relates to novel compounds that inhibit glucose-induced degradation-deficient (GID) E3 ligase, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related ...
|
|
WO/2024/071143A1 |
The present invention provides a photoelectric conversion element that exhibits excellent quantum efficiency when having received blue light. Also provided are an imaging element, a light sensor, a compound, and a compound production met...
|
|
WO/2024/064245A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases media...
|
|
WO/2024/062310A1 |
The present invention provides derivatives of (2S,3R,4R,5S,6R)-2-[4- chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]-phenyl]-6-(
hydroxymethyl)- oxan-3,4,5-triol (empagliflozin) and (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl...
|
|
WO/2024/057020A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2024/056096A1 |
The present invention relates to a crystal form of a nitrogen-containing heterocyclic ketone compound and a preparation method therefor. Specifically, the present invention relates to a salt having a compound represented by general formu...
|
|
WO/2024/051700A1 |
The present invention relates to a novel aryl ether substituted heterocyclic compound having GLP1R agonist activity. Specifically disclosed is a compound having a structure as represented by formula (I) as a GLP1R agonist, or a pharmaceu...
|
|
WO/2024/051816A1 |
Provided is a bicyclic PRMT5 inhibitor, which is a compound having a structure represented by formula (I). Further provided are a preparation method for the compound and use of the compound in regulating PRMT5 activity or treating PRMT5-...
|
|
WO/2024/052871A1 |
The object of the invention is a novel ruthenium complex of the general formula Ru-1, in which all the variable substituents have the meanings defined in the description. Also an object of the invention is a method for obtaining the ruth...
|
|
WO/2024/050815A1 |
Provided is the use of heteroaromatic ring compounds in nucleic acid tests. Particularly provided are the use of heteroaromatic ring compounds as a nucleic acid protective agent in nucleic acid tests, a method for inhibiting degradation ...
|
|
WO/2024/049977A1 |
Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are com...
|
|
WO/2024/046409A1 |
The present invention relates to a heterocyclic compound, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention relates to a heterocyclic compound as shown in general formula (I), a preparat...
|
|
WO/2024/046253A1 |
Provided in the present invention are a sodium channel regulator and the use thereof. The sodium channel regulator of the present invention has a brand-new structure and has an excellent in-vitro inhibitory effect on Nav 1.8. The compoun...
|
|
WO/2024/041613A1 |
The present disclosure relates to a heterocyclic compound, a method for preparing same, and pharmaceutical use thereof. Specifically, the present disclosure relates to a heterocyclic compound represented by general formula (I), a method ...
|
|
WO/2024/042146A2 |
The present invention provides covalent fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I) wherein X, n, p, and R1 to R4 are as described herein, compositions including the compounds, processes of manufa...
|
|
WO/2024/035950A1 |
Provided are compounds of the Formula (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.
|
